Lipella Pharmaceuticals gets ODD for LP-310 to treat GvHD
A clinical stage pipeline asset for the company, LP-310 is intended to be indicated for inflammatory diseases of the oral cavity, including oral lichen planus and oral GvHD.
Under the multi-year, multi-programme collaboration, the companies will discover, develop, and commercialise therapies for cancer patients. Prelude’s capabilities in medicinal chemistry, targeted protein degradation and clinical development will